First Time Loading...

Globus Medical Inc
NYSE:GMED

Watchlist Manager
Globus Medical Inc Logo
Globus Medical Inc
NYSE:GMED
Watchlist
Price: 50.55 USD 0.36% Market Closed
Updated: Apr 28, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Income Statement

1.6B
+28%
Revenue
Growth Rates:
1 Year
+53%
3 Years
+99%
5 Years
+120%
7 Years
+178%
10 Years
+261%
201.9m
-15%
Operating Income
Growth Rates:
1 Year
-15%
3 Years
+75%
5 Years
+14%
7 Years
+27%
10 Years
+60%
122.9m
-22%
Net Income
Growth Rates:
1 Year
-35%
3 Years
+20%
5 Years
-21%
7 Years
+18%
10 Years
+79%

Earnings Waterfall
Globus Medical Inc

Revenue
1.6B USD
Cost of Revenue
-548.2m USD
Gross Profit
1B USD
Operating Expenses
-818.5m USD
Operating Income
201.9m USD
Other Expenses
-79m USD
Net Income
122.9m USD

Income Statement
Globus Medical Inc

Rotate your device to view
Income Statement
Currency: USD
Dec-2013 Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Revenue
Revenue
434
N/A
444
+2%
450
+1%
461
+2%
474
+3%
492
+4%
512
+4%
531
+4%
545
+3%
553
+1%
556
+1%
555
0%
564
+2%
581
+3%
596
+3%
612
+3%
636
+4%
655
+3%
676
+3%
693
+3%
713
+3%
721
+1%
743
+3%
770
+4%
785
+2%
793
+1%
747
-6%
767
+3%
789
+3%
826
+5%
928
+12%
941
+1%
958
+2%
961
+0%
974
+1%
998
+3%
1 023
+2%
1 069
+5%
1 097
+3%
1 226
+12%
1 568
+28%
Gross Profit
Cost of Revenue
(99)
(101)
(104)
(106)
(111)
(118)
(124)
(129)
(132)
(132)
(132)
(130)
(135)
(139)
(143)
(149)
(151)
(153)
(153)
(154)
(159)
(163)
(170)
(177)
(180)
(187)
(194)
(205)
(218)
(224)
(237)
(238)
(239)
(243)
(248)
(255)
(264)
(275)
(283)
(353)
(548)
Gross Profit
335
N/A
343
+2%
346
+1%
355
+2%
364
+3%
374
+3%
388
+4%
402
+4%
412
+3%
421
+2%
424
+1%
425
+0%
429
+1%
442
+3%
452
+2%
463
+2%
486
+5%
502
+3%
522
+4%
539
+3%
554
+3%
558
+1%
573
+3%
592
+3%
605
+2%
606
+0%
554
-9%
562
+1%
572
+2%
602
+5%
691
+15%
703
+2%
719
+2%
718
0%
726
+1%
744
+2%
759
+2%
794
+5%
814
+3%
873
+7%
1 020
+17%
Operating Income
Operating Expenses
(209)
(211)
(213)
(216)
(219)
(226)
(236)
(244)
(248)
(252)
(253)
(255)
(270)
(286)
(298)
(309)
(319)
(330)
(346)
(363)
(377)
(390)
(404)
(418)
(429)
(438)
(454)
(455)
(456)
(461)
(465)
(474)
(524)
(529)
(530)
(543)
(523)
(548)
(566)
(635)
(818)
Selling, General & Administrative
(183)
(184)
(185)
(186)
(188)
(193)
(202)
(208)
(210)
(213)
(211)
(212)
(222)
(235)
(247)
(256)
(268)
(277)
(289)
(301)
(312)
(322)
(333)
(346)
(355)
(363)
(354)
(355)
(355)
(359)
(386)
(394)
(408)
(411)
(410)
(421)
(432)
(454)
(467)
(517)
(643)
Research & Development
(27)
(27)
(28)
(30)
(32)
(33)
(34)
(36)
(36)
(38)
(39)
(40)
(45)
(45)
(45)
(46)
(44)
(46)
(49)
(53)
(56)
(57)
(59)
(58)
(60)
(61)
(85)
(85)
(85)
(84)
(60)
(62)
(97)
(100)
(102)
(105)
(73)
(77)
(81)
(91)
(124)
Depreciation & Amortization
0
0
0
0
0
0
0
0
(2)
0
(0)
(1)
(4)
(5)
(6)
(8)
(8)
(8)
(9)
(9)
(10)
(11)
(12)
(13)
(14)
(14)
(15)
(16)
(17)
(18)
(18)
(19)
(19)
(18)
(18)
(18)
(18)
(18)
(18)
(27)
(51)
Operating Income
126
N/A
131
+4%
134
+2%
139
+4%
144
+4%
148
+2%
152
+3%
158
+4%
164
+4%
169
+3%
172
+2%
170
-1%
159
-6%
156
-2%
154
-1%
154
0%
166
+8%
171
+3%
176
+3%
176
N/A
177
+1%
169
-5%
169
+0%
175
+3%
177
+1%
168
-5%
100
-41%
107
+7%
115
+8%
141
+22%
226
+60%
229
+1%
195
-15%
189
-3%
196
+4%
201
+2%
236
+18%
245
+4%
248
+1%
238
-4%
202
-15%
Pre-Tax Income
Interest Income Expense
0
0
0
0
(0)
(0)
(0)
0
0
1
1
2
3
4
6
6
8
8
9
12
14
16
17
17
18
17
16
15
14
12
12
10
8
8
6
7
13
18
24
25
34
Non-Reccuring Items
(24)
(27)
(9)
(8)
(6)
(3)
(2)
(2)
8
8
6
5
(5)
(5)
(3)
(5)
(4)
(4)
(4)
(2)
(8)
(8)
(7)
(9)
(5)
(5)
(5)
(4)
(4)
(4)
(17)
(17)
(23)
(25)
(10)
(8)
(8)
(7)
(12)
(61)
(69)
Total Other Income
0
0
1
1
0
0
0
0
0
1
1
1
1
1
1
1
1
1
5
6
6
6
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
1
0
(2)
Pre-Tax Income
102
N/A
105
+3%
126
+20%
131
+4%
139
+6%
144
+4%
150
+4%
156
+4%
173
+11%
178
+3%
179
+0%
177
-1%
157
-11%
156
-1%
157
+1%
156
-1%
170
+9%
176
+3%
186
+6%
192
+3%
189
-2%
182
-3%
179
-2%
183
+2%
190
+4%
181
-5%
112
-38%
118
+6%
126
+7%
151
+20%
221
+47%
223
+1%
180
-19%
172
-5%
194
+13%
201
+4%
243
+21%
257
+6%
262
+2%
203
-23%
165
-18%
Net Income
Tax Provision
(33)
(35)
(43)
(45)
(46)
(48)
(50)
(53)
(60)
(62)
(61)
(59)
(53)
(51)
(49)
(49)
(52)
(46)
(41)
(36)
(32)
(32)
(36)
(37)
(35)
(33)
(23)
(23)
(24)
(29)
(38)
(36)
(31)
(30)
(39)
(46)
(53)
(56)
(57)
(45)
(43)
Income from Continuing Operations
69
70
83
86
93
96
99
103
113
116
118
118
104
105
108
107
118
129
146
155
157
150
143
147
155
148
89
95
102
122
184
187
149
142
155
155
190
201
204
158
123
Net Income (Common)
69
N/A
70
+2%
83
+19%
86
+3%
93
+8%
96
+4%
99
+4%
103
+3%
113
+10%
116
+3%
118
+1%
118
0%
104
-11%
105
+1%
108
+3%
107
-1%
107
N/A
118
+10%
135
+14%
144
+7%
157
+9%
150
-4%
143
-5%
147
+2%
155
+6%
148
-5%
89
-40%
95
+7%
102
+8%
122
+19%
184
+51%
187
+2%
149
-20%
142
-5%
155
+9%
155
+0%
190
+23%
201
+6%
204
+2%
158
-23%
123
-22%
EPS (Diluted)
0.73
N/A
0.74
+1%
0.88
+19%
0.9
+2%
0.97
+8%
1.01
+4%
1.04
+3%
1.08
+4%
1.17
+8%
1.21
+3%
1.23
+2%
1.22
-1%
1.08
-11%
1.09
+1%
1.11
+2%
1.1
-1%
1.09
-1%
1.17
+7%
1.32
+13%
1.41
+7%
1.54
+9%
1.48
-4%
1.42
-4%
1.45
+2%
1.52
+5%
1.45
-5%
0.91
-37%
0.94
+3%
1.01
+7%
1.19
+18%
1.77
+49%
1.81
+2%
1.44
-20%
1.36
-6%
1.49
+10%
1.55
+4%
1.85
+19%
1.98
+7%
2.02
+2%
1.37
-32%
1.07
-22%

See Also

Summary
GMED intrinsic value, competitors valuation, and company profile.
DCF Valuation
GMED stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GMED stock valuation using valuation multiples.
Wall Street Estimates
GMED price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GMED stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.